Although SIM exerts suppressive effects on expression and activation of MMPs52 and on melanoma cell migration capacity when co-administered with DMXAA9, our data suggested no significant modulation of MMP-2 and MMP-9 lytic activity by either LCL-SIM or LCL-DMXAA (Fig. 6E–G, P > 0.05). The gene discussed is MMP9; the disease is melanoma.